Navigation Links
A large step forward in the fight against African sleeping sickness

Each year, over 300,000 people die of African sleeping sickness (trypanosomiasis). Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) connected to the Free University of Brussels are making strides in the battle against this disease.

They have coupled the human protein ApoL-1 with a nanobody in order to very specifically eliminate the infection caused by the pathogenic parasites, against which our defense mechanism is powerless. Tests on mice are already promising. The recently published research results offer new possibilities for people who have contracted this disease.>African sleeping sickness
About 400,000 people worldwide suffer from the deadly African sleeping sickness. The disease produces severe sleep disorders that ultimately end in coma, followed by death. At present, fewer than 10% of the patients are treated in time. But on the other hand, the current treatment is also very toxic, and in many cases also results in the patient's death.

African sleeping sickness is a disorder caused by the trypanosome parasite. The blood-sucking tsetse fly transmits the parasite from person to person. Once someone has been infected by the parasite, the person's body has great difficulty getting the infection under control, because the parasite constantly changes appearance. Thus, the trypanosome remains impervious to the antibodies that the body produces.

Parasite eludes human defense mechanism
Fortunately, our body has a special defense mechanism that can help us in the fight against African trypanosomes. Our blood contains ApoL-1, which is toxic to − and neutralizes − most types of trypanosomes.

However, there is one trypanosome against which we are not protected: Trypanosoma brucei rhodesiense. This parasite is resistant to ApoL-1, because it has particular proteins that counteract ApoL-1's action.

For some time now, scientists have known that a variant of ApoL-1 i s not neutralized by Trypanosoma brucei rhodesiense. This truncated ApoL-1 variant can help to overcome the parasite that infects our body, but only when it is present in very high concentrations. The challenge for the researchers was to get this truncated ApoL-1 variant efficiently to the place where it is needed: onto the surface of the parasite.

Nanobody carries ApoL-1 variant to the parasite
Under the direction of Serge Muyldermans and Patrick De Baetselier, VIB researchers have previously produced a nanobody (a very small antibody) that targets and binds to the parasite very specifically (Stijlemans et al., 2004). Toya Nath Baral and his VIB colleagues have now succeeded in coupling this nanobody to the abbreviated ApoL-1 variant. This creates a special product that binds immediately to the parasite and thus brings the ApoL-1 variant to the place where it can carry out its neutralizing action.

All the tests performed on mice have been very promising: Trypanosome-infected mice survive after 1 treatment. The parasite is removed from the blood and all effects associated with the disease disappear. There is every indication that this substance can also counteract Trypanosoma brucei rhodesiense in humans − sparing them from African sleeping sickness.


'"/>

Source:VIB, Flanders Interuniversity Institute of Biotechnology


Related biology news :

1. Scientists discover unique microbe in Californias largest lake
2. Worlds largest rainforest drying experiment completes first phase
3. NASA study finds snow melt causes large ocean plant blooms
4. New project aims to make large-scale lobster farms feasible
5. Butterfly migration could be largest known
6. Amazon symposium to address large-scale conservation
7. Inhaling large amounts of salt can cause hypertension
8. Size matters: Preventing large mammal extinction
9. Carnegie Mellon University research reveals how cells process large genes
10. Updated data on novel HPV vaccine confirms efficacy in large population
11. Free-energy theory borne out in large-scale protein folding
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
Breaking Biology Technology: